Merck & Co. Inc. stock (US58933Y1055): Key cancer franchise drives fresh earnings spotlight

Merck & Co. Inc. has drawn renewed investor attention after its latest quarterly update highlighted strong growth for cancer drug Keytruda and raised full?year guidance, while also detailing pipeline progress and ongoing patent challenges.

Merck & Co. Inc. has been back in the spotlight after reporting first?quarter 2026 results that showed continued double?digit growth driven by its oncology and vaccines portfolio, led by Keytruda, and by slightly raising its full?year outlook, according to a company earnings release dated 04/25/2026 and subsequent coverage by Reuters as of 04/25/2026.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biotechnology and life sciences
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: Global prescription medicines, human vaccines, animal health
• Key revenue drivers: Oncology therapies such as Keytruda, vaccines, hospital acute care drugs
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co. Inc.: core business model

Merck & Co. Inc. is a large global pharmaceutical company focused on prescription medicines, vaccines and animal health products. The group generates the vast majority of its revenue from human health, with oncology and vaccines representing particularly important pillars within that segment, reflecting long?term investment in research and development.

The business is organized around therapeutic franchises, with oncology, vaccines, hospital acute care and immunology among the main focus areas. Merck invests heavily in clinical development and regulatory work to expand indications for existing products and to bring new drugs to market, according to its latest annual report published in early 2025 for the 2024 fiscal year, as summarized by SEC filings as of 02/29/2025.

A key feature of Merck’s model is the combination of blockbuster products with a diversifying early? and mid?stage pipeline. This allows the company to support current earnings while positioning itself for future patent expiries, an issue that is particularly relevant for Keytruda in the second half of the decade as biosimilar competition approaches and pricing dynamics may shift in major markets.

Main revenue and product drivers for Merck & Co. Inc.

In recent quarters, Merck’s financial performance has been dominated by oncology drug Keytruda, which is approved in multiple cancer indications across lung, melanoma, renal and other tumor types. Keytruda generated multi?billion?dollar quarterly revenue in the first quarter of 2026, growing at a double?digit percentage rate year over year, according to Merck’s Q1 2026 earnings release dated 04/25/2026 and summarized by Merck investor information as of 04/25/2026.

Beyond oncology, vaccines such as the human papillomavirus vaccine Gardasil continue to contribute materially to group sales. Gardasil demand has been supported by public health programs and broader vaccination campaigns in several regions, while also being subject to seasonality and tender dynamics. Hospital acute care products, including therapies for infectious diseases and critical care, form another recurring revenue stream for the company.

The animal health division is smaller than human pharmaceuticals but remains strategically relevant. It provides vaccines, anti?parasite treatments and other products for livestock and companion animals. This segment helps diversify cash flows and can behave differently over the economic cycle than human health, offering some resilience when individual drug franchises within the human portfolio face competitive or regulatory headwinds.

Conclusion

Merck & Co. Inc. remains heavily influenced by the success of Keytruda and other oncology and vaccine products, as illustrated by its Q1 2026 results and updated guidance. For US investors, the stock offers exposure to a large pharmaceutical franchise with a significant presence on the New York Stock Exchange, but it also faces typical sector risks such as patent expiries, regulatory scrutiny and competitive pressure. The balance between current blockbuster earnings and the strength of the development pipeline will likely remain a central focus in how the market assesses Merck’s long?term trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.